Funding
← Back to your selection

GV (Google Ventures)

Activity from announced rounds

Activity in this selectionUnited States · Oct 19, 2026 · Jul 22, 2026

GV invests in technology and life-science companies, including AI applications, developer tools, cybersecurity, computing infrastructure and healthcare.

Its AI interests span the stack: new computing systems and inference infrastructure, tools for developers, software for professional workflows and applications in drug discovery and patient care. This gives both infrastructure founders and application builders a route to a specialist investment team.

GV developed the design sprint, a five-day process that takes a business question through problem definition, prototyping and customer testing. Its published sprint materials help teams test demand and product decisions before committing to a full launch.

Sources
Rounds participated in
8
Confirmed lead rounds
1
3 roles undisclosed
New companies
7
First participation on record · 1 follow-on
Funding in participating rounds
$1.4B
8 disclosed · full round size, not this investor’s share

By stage

Series C+3
Series B2
Undisclosed2
Series A1

By primary sector

Biotech3
Cybersecurity2
AI1
Developer tools1
Healthtech1

By country

United States8

Rounds

8 in this selection
Estuary Biotherapeutics

Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.

$93MSeries A
Participant
Allara

Virtual care for women with hormonal, metabolic and reproductive health needs.

$30MFunding
Participant
Armadin

Armadin develops AI agents that test attack paths across enterprise systems and show defenders how connected weaknesses could be exploited.

$255.5MSeries B
Participant
Snorkel AI

Snorkel AI helps enterprises build expert-curated training data and benchmarks for advanced AI models and agents.

$350MSeries E
Participant
Encoded Therapeutics Inc.

Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.

$275MSeries F
Lead
Blacksmith

Cloud infrastructure for validating and testing AI-generated code faster

$45MSeries B
Role not disclosed
LifeMine Therapeutics

Develops fungal genome-derived therapeutics for organ transplant rejection

$263MSeries D+Series E
Role not disclosed
Obsidian Security

Secures non-human identities and AI agents operating in third-party applications

$85MSeries D
Role not disclosed